The administration calls it a "workaround" that resets a 7 to 11 year clock before Medicare can negotiate a price; drugmakers say closing it would punish legitimate research on already approved medicines.
The Trump administration on Friday proposed a rule change targeting drugmakers who add active ingredients to already-approved products, a move it frames as protecting "program integrity" in Medicare's price-negotiation program. Under current rules, certain product modifications can reset a clock that runs for seven to eleven years after FDA approval before the government can negotiate a lower price.
The rule, issued by the Centers for Medicare & Medicaid Services, sits inside the annual process for choosing the next set of drugs subject to negotiation. It is a proposal, not a final policy, and opens a public comment period before any change takes effect.
The mechanism behind the fight is a design choice. Congress set Medicare's negotiation clock to begin seven years after FDA approval for small-molecule drugs and eleven years for biologics, a window meant to give manufacturers time to recoup research investment before price controls take hold. Critics say drugmakers have learned to extend that window by adding an active ingredient to an approved product, which under existing guidance can qualify the modified version as a new drug and restart the clock. The administration describes the practice as a "workaround." Drugmakers respond that adding active ingredients can reflect real clinical improvement for patients, and warn that closing the option would penalize a legitimate class of research on already-approved medicines.
The proposal is not new. The administration considered a similar policy last year and put off a decision to study it further, according to STAT's reporting on the proposed rule.
The calendar matters for anyone who wants to weigh in. The next twenty drugs selected for Medicare negotiation will be announced by February 1, 2027, and any negotiated prices will take effect in 2029. Between now and a final rule, the comment period is the moment when manufacturers, patient groups, and policy analysts can press their view of what counts as a new drug. Whether the proposed fix closes one opening cleanly or simply pushes companies toward another is the question the comment record will help answer.